These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 9343164)
41. Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine. Igarashi T; Ami Y; Yamamoto H; Shibata R; Kuwata T; Mukai R; Shinohara K; Komatsu T; Adachi A; Hayami M J Gen Virol; 1997 May; 78 ( Pt 5)():985-9. PubMed ID: 9152414 [TBL] [Abstract][Full Text] [Related]
42. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. Rasmussen RA; Ong H; Song R; Chenine AL; Ayash-Rashkovsky M; Hu SL; Polacino P; Else JG; Novembre FJ; Ruprecht RM; AIDS; 2007 Sep; 21(14):1841-8. PubMed ID: 17721091 [TBL] [Abstract][Full Text] [Related]
43. Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles. Willey RL; Byrum R; Piatak M; Kim YB; Cho MW; Rossio JL; Bess J; Igarashi T; Endo Y; Arthur LO; Lifson JD; Martin MA J Virol; 2003 Jan; 77(2):1163-74. PubMed ID: 12502833 [TBL] [Abstract][Full Text] [Related]
44. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. Buge SL; Richardson E; Alipanah S; Markham P; Cheng S; Kalyan N; Miller CJ; Lubeck M; Udem S; Eldridge J; Robert-Guroff M J Virol; 1997 Nov; 71(11):8531-41. PubMed ID: 9343211 [TBL] [Abstract][Full Text] [Related]
45. Depo-Provera abrogates attenuated lentivirus-induced protection in male rhesus macaques challenged intravenously with pathogenic SIVmac239. Genescà M; Li J; Fritts L; Chohan P; Bost K; Rourke T; Blozis SA; McChesney MB; Miller CJ J Med Primatol; 2007 Aug; 36(4-5):266-75. PubMed ID: 17669215 [TBL] [Abstract][Full Text] [Related]
46. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. De Rose R; Batten CJ; Smith MZ; Fernandez CS; Peut V; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Venturi V; Davenport MP; Kent SJ J Virol; 2007 Jan; 81(1):292-300. PubMed ID: 17050602 [TBL] [Abstract][Full Text] [Related]
47. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230 [TBL] [Abstract][Full Text] [Related]
48. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques. Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899 [TBL] [Abstract][Full Text] [Related]
49. Inhibition of simian immunodeficiency virus (SIV) replication by CD8(+) T lymphocytes from macaques immunized with live attenuated SIV. Gauduin MC; Glickman RL; Means R; Johnson RP J Virol; 1998 Aug; 72(8):6315-24. PubMed ID: 9658070 [TBL] [Abstract][Full Text] [Related]
50. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1. Dunn CS; Hurtrel B; Beyer C; Gloeckler L; Ledger TN; Moog C; Kieny MP; Mehtali M; Schmitt D; Gut JP; Kirn A; Aubertin AM AIDS Res Hum Retroviruses; 1997 Jul; 13(11):913-22. PubMed ID: 9223407 [TBL] [Abstract][Full Text] [Related]
51. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. Buge SL; Murty L; Arora K; Kalyanaraman VS; Markham PD; Richardson ES; Aldrich K; Patterson LJ; Miller CJ; Cheng SM; Robert-Guroff M J Virol; 1999 Sep; 73(9):7430-40. PubMed ID: 10438833 [TBL] [Abstract][Full Text] [Related]
52. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. Vogel TU; Reynolds MR; Fuller DH; Vielhuber K; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Marthas ML; Erfle V; Wolinsky SM; Wang C; Allison DB; Rud EW; Wilson N; Montefiori D; Altman JD; Watkins DI J Virol; 2003 Dec; 77(24):13348-60. PubMed ID: 14645590 [TBL] [Abstract][Full Text] [Related]
53. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. Quesada-Rolander M; Mäkitalo B; Thorstensson R; Zhang YJ; Castaños-Velez E; Biberfeld G; Putkonen P AIDS Res Hum Retroviruses; 1996 Jul; 12(11):993-9. PubMed ID: 8827215 [TBL] [Abstract][Full Text] [Related]
54. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745 [TBL] [Abstract][Full Text] [Related]
55. Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine. Nixon DF; Donahoe SM; Kakimoto WM; Samuel RV; Metzner KJ; Gettie A; Hanke T; Marx PA; Connor RI Virology; 2000 Jan; 266(1):203-10. PubMed ID: 10612675 [TBL] [Abstract][Full Text] [Related]
56. Vaccine protection against simian immunodeficiency virus infection. Desrosiers RC; Wyand MS; Kodama T; Ringler DJ; Arthur LO; Sehgal PK; Letvin NL; King NW; Daniel MD Proc Natl Acad Sci U S A; 1989 Aug; 86(16):6353-7. PubMed ID: 2548210 [TBL] [Abstract][Full Text] [Related]
57. High beta-chemokine expression levels in lymphoid tissues of simian/human immunodeficiency virus 89.6-vaccinated rhesus macaques are associated with uncontrolled replication of simian immunodeficiency virus challenge inoculum. LaFranco-Scheuch L; Abel K; Makori N; Rothaeusler K; Miller CJ J Virol; 2004 Jun; 78(12):6399-408. PubMed ID: 15163733 [TBL] [Abstract][Full Text] [Related]
58. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses. Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096 [TBL] [Abstract][Full Text] [Related]
59. Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals. Greenier JL; Van Rompay KK; Montefiori D; Earl P; Moss B; Marthas ML Virol J; 2005 Feb; 2():11. PubMed ID: 15710048 [TBL] [Abstract][Full Text] [Related]
60. Prior infection with a nonpathogenic chimeric simian-human immunodeficiency virus does not efficiently protect macaques against challenge with simian immunodeficiency virus. Letvin NL; Li J; Halloran M; Cranage MP; Rud EW; Sodroski J J Virol; 1995 Jul; 69(7):4569-71. PubMed ID: 7769725 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]